NASDAQ:RXST RxSight (RXST) Stock Price, News & Analysis $29.66 -0.67 (-2.19%) As of 01:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About RxSight Stock (NASDAQ:RXST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RxSight alerts:Sign Up Key Stats Today's Range$29.55▼$30.8650-Day Range$29.81▼$38.4952-Week Range$26.29▼$66.54Volume165,419 shsAverage Volume593,354 shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice Target$58.13Consensus RatingModerate Buy Company OverviewRxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Read More… RxSight Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreRXST MarketRank™: RxSight scored higher than 54% of companies evaluated by MarketBeat, and ranked 517th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingRxSight has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageRxSight has only been the subject of 4 research reports in the past 90 days.Read more about RxSight's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for RxSight are expected to grow in the coming year, from ($0.70) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RxSight is -35.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RxSight is -35.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRxSight has a P/B Ratio of 6.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about RxSight's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.06% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RxSight has recently increased by 1.75%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRxSight does not currently pay a dividend.Dividend GrowthRxSight does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.06% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RxSight has recently increased by 1.75%, indicating that investor sentiment is decreasing. News and Social Media1.8 / 5News Sentiment0.24 News SentimentRxSight has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for RxSight this week, compared to 5 articles on an average week.Search Interest1 people have searched for RXST on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added RxSight to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, RxSight insiders have sold 1,471.26% more of their company's stock than they have bought. Specifically, they have bought $44,993.00 in company stock and sold $706,956.00 in company stock.Percentage Held by InsidersOnly 9.36% of the stock of RxSight is held by insiders.Percentage Held by Institutions78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about RxSight's insider trading history. Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Email Address RXST Stock News HeadlinesStifel Nicolaus Remains a Hold on RxSight (RXST)February 18 at 9:20 AM | markets.businessinsider.comBrokerages Set RxSight, Inc. (NASDAQ:RXST) Target Price at $58.13February 13, 2025 | americanbankingnews.comThe FED is losing the war on inflation It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…February 21, 2025 | WealthPress (Ad)Insider Stock Buying Reaches US$1.83m On RxSightFebruary 2, 2025 | finance.yahoo.comRxSight director sells $108,618 in common stockJanuary 27, 2025 | msn.comRxSight price target lowered to $43 from $66 at NeedhamJanuary 17, 2025 | markets.businessinsider.comRxSight’s Promising Growth Fueled by Strong Market Performance and Strategic ExpansionJanuary 13, 2025 | markets.businessinsider.comRxSight (RXST) Receives a Buy from Bank of America SecuritiesJanuary 13, 2025 | markets.businessinsider.comSee More Headlines RXST Stock Analysis - Frequently Asked Questions How have RXST shares performed this year? RxSight's stock was trading at $34.38 at the beginning of 2025. Since then, RXST stock has decreased by 12.8% and is now trading at $29.9750. View the best growth stocks for 2025 here. How were RxSight's earnings last quarter? RxSight, Inc. (NASDAQ:RXST) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.18. The firm earned $35.31 million during the quarter, compared to the consensus estimate of $35.15 million. RxSight had a negative net margin of 23.92% and a negative trailing twelve-month return on equity of 14.00%. When did RxSight IPO? RxSight (RXST) raised $125 million in an initial public offering on Friday, July 30th 2021. The company issued 7,350,000 shares at $16.00-$18.00 per share. Who are RxSight's major shareholders? RxSight's top institutional shareholders include RA Capital Management L.P. (9.29%), Vanguard Group Inc. (5.91%), Bank of America Corp DE (5.36%) and Artisan Partners Limited Partnership (3.85%). Insiders that own company stock include Ronald M Md Kurtz, Eric Weinberg, Ilya Goldshleger, Julie Andrews, Robert Keith Warner, William J Phd Link, Shelley B Thunen, Shweta Maniar and Jesse Anderson Corley. View institutional ownership trends. How do I buy shares of RxSight? Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of RxSight own? Based on aggregate information from My MarketBeat watchlists, some other companies that RxSight investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), ServiceNow (NOW), Arista Networks (ANET) and Disc Medicine (IRON). Company Calendar Last Earnings11/07/2024Today2/21/2025Next Earnings (Estimated)2/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Ophthalmic goods Sub-IndustryMedical Equipment Current SymbolNASDAQ:RXST CUSIPN/A CIK1111485 Webwww.rxsight.com Phone949-521-7830FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Stock Price Target$58.13 High Stock Price Target$73.00 Low Stock Price Target$35.00 Potential Upside/Downside+91.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,610,000.00 Net Margins-23.92% Pretax Margin-23.91% Return on Equity-14.00% Return on Assets-12.51% Debt Debt-to-Equity RatioN/A Current Ratio12.67 Quick Ratio11.71 Sales & Book Value Annual Sales$89.08 million Price / Sales13.72 Cash FlowN/A Price / Cash FlowN/A Book Value$4.47 per share Price / Book6.79Miscellaneous Outstanding Shares40,300,000Free Float36,532,000Market Cap$1.22 billion OptionableOptionable Beta1.19 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:RXST) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.